In an article published in Nature Genetics, researchers confirm that about 14% of all cases of cerebral palsy, a disabling brain disorder for which there are no cures, may be linked to a patient’s genes and suggest that many of those genes control how brain circuits become wired during early development. This conclusion is based on the largest genetic study of cerebral palsy ever conducted. The results led to recommended changes in the treatment of at least three patients, highlighting the importance of understanding the role genes play in the disorder. The work was largely funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.
“Our results provide the strongest evidence to date that a significant portion of cerebral palsy cases can be linked to rare genetic mutations, and in doing so identified several key genetic pathways involved,” said Michael Kruer,
Phoenix, Arizona–(Newsfile Corp. – September 24, 2020) – The Stock Day Podcast welcomed US Nuclear Corp. (OTC Pink: UCLE) (“the Company”), a radiation and chemical detection holding company specializing in the development, manufacturing, and sales of radiation and chemical detection instrumentation. CEO of the Company, Bob Goldstein, joined Stock Day host Everett Jolly.
Jolly began the interview by asking about the Company’s partner, Grapheton, and its development of neural stimulation technology. “Grapheton is the only company in the world that makes biocompatible electrodes, and also biocompatible smart chips that can be implanted under the skin or in the scalp,” explained Goldstein. “Grapheton is also the only company that is constantly measuring the changing chemistry in the brain,” he continued. “With the brain-computer interface, the idea is that it will be doing two-way discussions with the brain to assist and augment with its many functions.”